

Independent Auditor's Report

To
Trustees
Tata Capital Healthcare Fund I

Report on the audit of the Financial Statements

Opinion

1. We have audited the accompanying Financial Statements of Tata Capital Healthcare Fund I ('the Fund'), which comprise the Balance Sheet as at 31 March 2026, and the Statement of Profit and loss and the Cash Flow Statement for the year ended on that date, and notes to the Financial Statements, including a summary of significant accounting policies and other explanatory information ('the Financial Statements').
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements are prepared and presented as required by the Guidance Note on Financial Statements of Non- Corporate Entities issued by Institute of Chartered Accountants of India ('ICAI') and give a true and fair view in conformity with the Accounting Standards issued by the ICAI read with Securities and Exchange Board of India (Alternative Investment Funds) Regulations, 2012 (as amended), of the state of affairs of the Fund as at 31 March 2026, and its loss and its cash flows for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing ('SAs') issued by ICAI. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Fund in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the Financial Statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the Financial Statements.

Emphasis of Matter

4. Attention is drawn to Note I in the financial statements, which describe that as at balance sheet date, the Fund continues to hold one portfolio investment, and in accordance with Securities and Exchange Board of India's (Alternative Investment Funds) (third amendment) Regulations, 2024 notification dated 11 July 2024 has registered itself as a "migrated venture capital fund" under these regulations. The liquidation period for "migrated venture capital fund will end on July 19, 2026. The Investment Manager believes that it has sufficient time to take appropriate action to effect an orderly liquidation of the portfolio investments of the Fund. Accordingly, the Investment Manager has prepared the financial statements of the Fund on a liquidation basis i.e. assets are measured at lower of carrying amount and estimated net realizable values and liabilities are stated at their estimated settlement amounts in the financial statements. Our opinion is not modified in respect of this matter.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

5. The Trustees and Investment Manager with respect to the preparation of these Financial Statements that give a true and fair view of the State of Affairs, Loss and Cash Flows of the Fund in accordance with the Accounting Principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records or safeguarding of the assets of the Fund and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; design, implementation and maintenance of adequate internal financial controls, for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
6. In preparing the Financial Statements, the Investment manager is responsible for assessing the Fund's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Investment manager either intends to liquidate the Fund or to cease operations, or has no realistic alternative but to do so. In the present case, liquidation basis of accounting has been used since the Investment manager has concluded that the use of going concern basis is not appropriate in the facts and circumstances as stated in Note 1 to the financial statements.



7. Investment manager is also responsible for overseeing the Fund's financial reporting process.

Auditor's responsibilities for the audit of the Financial Statements

8. Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.
9. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- 9.1. Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - 9.2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing opinion on effectiveness of the entity's internal control.
 - 9.3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Investment manager.
 - 9.4. Conclude on the appropriateness of the Investment manager's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Fund to cease to continue as a going concern.
 - 9.5. Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.
10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
11. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For **KKC & Associates LLP**

Chartered Accountants

(formerly Khimji Kunverji & Co LLP)

Firm Registration Number: 105146W/W100621

Soorej Kombaht

Partner

ICAI Membership No: 164366

UDIN: 26164366RPLXNB9957

Place: Mumbai

Date: 20 April 2026



Tata Capital Healthcare Fund I

Balance sheet

as at 31 March 2026

Currency: In Indian Rupees

Particulars	Note	As at 31 March 2026 ₹	As at 31 March 2025 ₹
I. CAPITAL AND LIABILITIES			
1. Unitholders' funds			
(a) Fund corpus		1,000	1,000
(b) Unit capital			
Class A	3(a)	79,74,52,524	79,78,48,497
Class B	3(b)	-	-
(c) Reserves and surplus	4	(79,83,16,209)	(77,42,27,098)
2 Current liabilities			
(a) Trade payables			
Total outstanding amount dues of micro enterprises and small enterprises	5	-	-
Total outstanding amount dues of creditors other than micro enterprises and small enterprises		9,88,024	2,15,407
(b) Other current liabilities	6	29,24,504	39,00,550
TOTAL		30,49,843	2,77,38,356
II. ASSETS			
(a) Long-term loans and advances	7	-	6,32,565
2. Current assets			
(a) Current portion of long term investments	8	-	-
(b) Cash and bank balances	9	29,24,889	2,71,04,491
(c) Short-term loans and advances	10	1,24,954	1,300
TOTAL		30,49,843	2,77,38,356

Significant accounting policies

Accompanying notes are integral part of the financial statements

2

3-18

In terms of our report of even date attached

For KKC & Associates LLP
(formerly Khimji Kunverji & Co LLP)
Chartered Accountants
Firm Registration No: 105146W/W100621

Soorej Kombaht
Partner
Membership No: 164366
Mumbai
20 April 2026



Rajiv Sabharwal
Managing Director & CEO
Tata Capital Limited-
Investment Manager

Director
Tata Trustee Company
Private Limited
Mumbai

For and on behalf of the Fund
Tata Capital Healthcare Fund I

Visalakshi Chandramouli
Managing Partner
Tata Capital Limited-
Investment Manager

Director
Tata Trustee Company
Private Limited
Mumbai



Tata Capital Healthcare Fund I

Statement of Profit and Loss

for the year ended on 31 March 2026

Currency: In Indian Rupees

Particulars	Note	For the year ended 31 Mar 2026	For the year ended 31 March 2025
		₹	₹
Income			
Revenue from operations	11	10,25,380	1,10,97,690
Net gain on sale of long term investment	12	-	19,82,30,312
Other income	13	30,821	-
Total income		<u>10,56,201</u>	<u>20,93,28,002</u>
Expenses			
Operating expenses	14	<u>29,26,835</u>	<u>26,83,484</u>
Total expenses		<u>29,26,835</u>	<u>26,83,484</u>
(Loss) before tax		<u>(18,70,635)</u>	<u>20,66,44,518</u>
Tax expense:			
Current tax		<u>3,72,787</u>	<u>6,67,256</u>
Total tax expense		<u>3,72,787</u>	<u>6,67,256</u>
(Loss) for the year		<u>(22,43,422)</u>	<u>20,59,77,262</u>

Significant accounting policies 2
Accompanying notes are integral part of the financial statements 3-18

In terms of our report of even date attached

For KKC & Associates LLP
(formerly Khimji Kunverji & Co LLP)
Chartered Accountants
Firm Registration No: 105146W/W100621

Soorej Kombaht

Soorej Kombaht
Partner
Membership No: 164366
Mumbai
20 April 2026



For and on behalf of the Fund
Tata Capital Healthcare Fund I

Rajiv Sabharwal

Rajiv Sabharwal
Managing Director & CEO
Tata Capital Limited-
Investment Manager

Visalakshi

Visalakshi Chandramouli
Managing Partner
Tata Capital Limited-
Investment Manager

Narayan

Director
Tata Trustee Company Private
Limited
Mumbai

Kunwar

Director
Tata Trustee Company Private
Limited
Mumbai



Tata Capital Healthcare Fund I

Cash flow statement

for the year ended on 31 March 2026

Currency: In Indian Rupees

Particulars	For the year ended 31 March 2026 ₹	For the year ended 31 March 2025 ₹
A. Cash flows from operating activities		
(Loss) before tax	(18,70,635)	20,66,44,518
Adjustments for :		
a) Interest income	(10,25,380)	(14,82,836)
b) Interest on income tax refund	(30,821)	(96,14,854)
c) Net gain from sale of long term investments	-	(19,82,30,312)
Operating profit before working capital changes	(29,26,836)	(26,83,484)
Changes in working capital:		
Adjustments for (increase)/ decrease in operating assets:		
Short term loans and advances	(1,23,654)	38,124
Adjustments for increase / (decrease) in operating liabilities:		
Trade payables	7,72,617	(28,81,634)
Other current liabilities	(9,76,046)	(5,71,033)
Cash from operating activities before taxes	(32,53,919)	(60,98,027)
Taxes (paid)/ refund	1,65,645	(11,94,181)
Net cash from operating activities (A)	(30,88,274)	(72,92,209)
B. Cash flows from investing activities		
Net proceeds from sale of long term investments	-	44,45,90,312
Dividend received	-	96,14,854
Interest received	10,25,380	14,82,836
Net cash from investing activities (B)	10,25,380	45,56,88,002
C. Cash flows from financing activities		
Repayment of Capital to Class A unitholders	(3,95,973)	(24,55,68,055)
Distribution to Class A unitholders	(1,76,596)	(10,95,18,220)
Distribution to Class B unitholder	(2,16,69,093)	(6,73,88,760)
Net cash generated from financing activities (C)	(2,22,41,662)	(42,24,75,036)
D. Net (decrease)/increase in cash and bank balances (A+B+C)	(2,43,04,556)	2,59,20,759
Cash and bank balances at the beginning of the year		
Bank balance in current account	13,35,612	11,83,732
Fixed deposit with original maturity of 3 months or less	2,57,68,879	-
	2,71,04,491	11,83,732
Cash and bank balances at end of the year		
Bank balance in current account	14,89,308	13,35,612
Fixed deposit with original maturity of 3 months or less	14,35,581	2,57,68,879
	27,99,935	2,71,04,491
E. Reconciliation of cash and bank balances		
cash and bank balances at end of the year	14,89,308	13,35,612
Add: Fixed deposit with original maturity of 3 months or less	14,35,581	2,57,68,879
Cash and bank balances as per Note 9	29,24,889	2,71,04,491

Cash flow statement has been prepared in accordance with AS - 3 "cash flow statements indirect method"

Significant accounting policies

Accompanying notes are integral part of the financial statements

In terms of our report of even date attached

For KKC & Associates LLP
(formerly Khimji Kunverji & Co LLP)
Chartered Accountants
Firm Registration No: 105146W/W100621

Soorej Kombhaht
Partner
Membership No: 164366
Mumbai
20 April 2026



Rajiv Sabharwal

Rajiv Sabharwal
Managing Director & CEO
Tata Capital Limited-
Investment Manager

Visalakshi

Visalakshi Chandramouli
Managing Partner
Tata Capital Limited-
Investment Manager

Nareg

Director
Tata Trustee
Company Private
Limited
Mumbai

huyy

Director
Tata Trustee
Company Private
Limited
Mumbai



Tata Capital Healthcare Fund I

Notes to the financial statements (*continued*)

for the year ended on 31 March 2026

Currency: In Indian Rupees

1. About the Fund

Tata Capital Healthcare Fund I (the “Fund”) is set up as a determinate Trust under the Indian Trust Act, 1882. The Fund is registered with the Securities and Exchange Board of India (“SEBI”) as a venture capital fund under the SEBI (Venture Capital Funds) Regulations, 1996 (and amendments thereto as applicable), vide Registration Number IN/VCF/09-10/157. As per SEBI guidelines, the Fund is now converted into Category I Alternative Investment Fund – Venture Capital Fund (Migrated), vide Registration Number IN/AIF1/25-26/1952.

Tata Trustee Company Private Limited (the “Trustee”) (formerly known as Tata Trustee Company Limited) is the trustee of the Fund. The Trustees have appointed Tata Capital Limited as the “Investment Manager”.

The Fund is a close ended fund established to capture the benefits of opportunities in healthcare by investing in companies having high growth potential and in the expansion/development phase. The Fund offers two classes of units – Class A Units to the contributors and Class B Units to the Investment Manager or such other person as the Investment Manager may recommend.

As at balance sheet date, the Fund continues to hold one portfolio investment. The Fund has registered itself as a “migrated venture capital fund” in accordance with Securities and Exchange Board of India’s (Alternative Investment Funds) (third amendment) Regulations, 2024 notification dated 11 July 2024. The liquidation period for “migrated venture capital fund” ends on July 19, 2026. The Investment Manager believes that it has sufficient time to take appropriate action to effect an orderly liquidation of the portfolio investments of the Fund. Accordingly, the Investment Manager has prepared the financial statements of the Fund on a liquidation basis.

2. Significant accounting policies

i) Basis of preparation of financial statements

The financial statements comprising of Balance Sheet, Statement of Profit and Loss, Cash Flow Statement and the accompanying notes of the Fund have been prepared and presented in accordance with the Accounting Standards (“AS”) prescribed by the Institute of Chartered Accountants of India (“ICAI”) for non-company entities, as applicable to the Fund based on its classification under the revised criteria announced by the ICAI Council at its 433rd meeting held on August 13–15, 2024, effective for accounting periods commencing on or after April 1, 2024 and in compliance with the requirements of the Securities and Exchange Board of India (Alternative Investment Funds) Regulations, 2012, as amended (“SEBI AIF Regulations”) issued by the Securities and Exchange Board of India (“SEBI”).

The Fund, being a trust registered under the Indian Trusts Act, 1882 and not being a corporate entity within the meaning of the Companies Act, 2013, constitutes a Non-Corporate Entity and accordingly, the financial statements have been prepared and presented in conformity with the ICAI Guidance Note on Financial Statements of Non-Corporate Entities (hereinafter referred to as “the Guidance Note”). The formats for the Balance Sheet, Statement of Profit and Loss, and the accompanying notes prescribed in the Guidance Note have been adopted in the preparation of these financial statements.



Tata Capital Healthcare Fund I

Notes to the financial statements *(continued)*

for the year ended on 31 March 2026

Currency: In Indian Rupees

2. Significant accounting policies *(continued)*

ii) Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles ('GAAP') in India requires the Investment Manager to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses and disclosure of contingent assets and liabilities as on date of the financial statements. The estimates and assumptions used in the accompanying financial statements are based upon Investment Manager's evaluation of the relevant facts and circumstances as of the date of the financial statements. Actual results may differ from the estimates and assumptions used in preparing the accompanying financial statements. Such differences are recognised in future periods.

iii) Revenue recognition

Interest income on fixed deposits is accrued proportionately based on period for which the same is placed. Dividend income is recognised when the right to receive the income is established. Interest on delayed contributions is recognised on receipt basis.

iv) Expenditure

i) Investment management fees are accrued evenly over the period to which they relate, on the basis of the agreed terms and are charged to Statement of Profit and Loss (refer note 14(ii)).

ii) Other expenses incurred by the Investment Manager on behalf of the Fund are charged to the Statement of Profit and Loss of the Fund in the year in which such costs are incurred.

v) Investments

Portfolio investments made by the Fund are initially classified as Long term investments. Such Investments are reclassified as Current Investments when the Investment Manager is actively engaged in/negotiating for disposing off these Investments. Long term investments are carried at cost, less provision for other than temporary diminution in value, if any. Investments held for sale are stated at cost or market value whichever is lower. Cost includes purchase cost and related expenses such as brokerage and stamp duties. The differences between cost and redemption/sale proceeds net of expenses are recognized in the Statement of Profit and Loss in the period in which the transaction of sale / redemption is effected. For calculation of profit/loss on investments, cost is calculated using first in-first out method.

Pursuant to the requirements of Regulation 23 of the SEBI AIF Regulations, which prescribes the valuation framework for investments, Investments of the Fund are measured at Fair Value in accordance with the valuation policy approved by the Investment Manager and the Trustee and in conformity with Regulation 23 of the SEBI AIF Regulations read with the applicable Master Circular for Alternative Investment Funds issued by SEBI.

vi) Cash and bank balances (for purposes of Cash Flow Statement)

Cash comprises cash on hand and demand deposits with banks. Cash balances are short-term deposits with banks (with original maturity of three months or less from the date of acquisition) and highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

Cash flow statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Fund are segregated based on the available information.



Tata Capital Healthcare Fund I

Notes to the financial statements *(continued)*

for the year ended on 31 March 2026

Currency: In Indian Rupees

2. Significant accounting policies *(continued)*

vii) Foreign currency

Initial recognition

Transactions in foreign currencies entered into by the Fund are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction.

Measurement at the balance sheet date

Foreign currency monetary items (other than derivative contracts) of the Fund, outstanding at the balance sheet date are restated at the year-end rates. Non-monetary items of the Fund are carried at historical cost.

viii) Provisions and contingencies

A provision is recognised when the Fund has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, but probably will not, require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions but are disclosed unless the possibility of outflow of resources is remote.

Contingent assets are not recognised in the financial statements. However, they are assessed continually, and if it has become virtually certain that inflow of economic benefits will arise, the asset and related income are recognized in the financial statements.

The accounting policies adopted in the preparation of these financial statements are consistent with those applied in the immediately preceding financial year.



Tata Capital Healthcare Fund I

Notes to the financial statements (continued)

for the year ended on 31 March 2026

Currency: In Indian Rupees

3(a) Unit capital

i) Details of Class A units issued, outstanding and paid up

	As at 31 March 2026 ₹	As at 31 March 2025 ₹
Issued		
3,195,300,000 units (previous year 3,195,300,000) of Class A units of ₹1 each	3,195,300,000	3,195,300,000
Subscribed and paid up		
3,195,300,000 units (previous year: 3,195,300,000 units) of ₹1 each	797,452,524	797,848,497
Total	797,452,524	797,848,497

ii) Reconciliation of number and paid up value of Class A units issued and outstanding

Particulars	For the year ended 31 March 2026		For the year ended 31 March 2025	
	No of Class A units	₹	No of Class A units	₹
Units outstanding/paid up at the beginning of the year	3,195,300,000	797,848,497	3,195,300,000	1,043,416,552
Paid up during the year	-	-	-	-
Less: Repayment of Capital to Contributors	-	(395,973)	-	(245,568,055)
Units outstanding/paid up at the end of the year	3,195,300,000	797,452,524	3,195,300,000	797,848,497

iii) Details of Class A Unit Holders holding more than 5% of Class A unit capital

Name of unit holder	As at 31 March 2026		As at 31 March 2025	
	No of Class A units	% of holding	No of Class A units	% of holding
Tata Capital Ltd	1,000,000,000	31.30	1,000,000,000	31.30
Vibha Dilip Shanghvi	250,000,000	7.82	250,000,000	7.82

iv) Beneficial interest and rights of unit holders

The beneficial interest and rights of the Class A unit holders are specified in the Contribution Agreement entered into with Class A unit holders.

Distributions by the Fund will be in the order of priority as defined in the Contribution Agreement/Private Placement Memorandum of the Fund. Holders of Class A units are entitled to return of paid up capital prior to return of paid up capital to the Holders of Class B units. Preferred Return needs to be paid to Class A holders prior to paying any Distributable Proceeds in excess of paid up capital of Class A and Class B unit holders, to Class B unit holders.

Class A unit holders are entitled to one vote for each Class A unit held.



(Signature)

Tata Capital Healthcare Fund I

Notes to the financial statements (continued)

for the year ended on 31 March 2026

Currency: In Indian Rupees

3(b) Unit capital

i) Details of Class B units issued, outstanding and paid up

Unit Capital	As at 31 March 2026 ₹	As at 31 March 2025 ₹
Issued, Subscribed and fully paid up 10,000 Class B units (Previous year: 10,000 units) of ₹1 each	-	-

ii) Reconciliation of number and paid up value of Class B units issued and outstanding

Particulars	For the year ended 31 March 2026		For the year ended 31 March 2025	
	Number of Class B units	₹	Number of Class B units	₹
Units outstanding and paid up at the beginning of the year	10,000	-	10,000	-
Less: repayment of capital to Contributor	-	-	-	-
Units outstanding and paid up at the end of the year	10,000	-	10,000	-

iii) Beneficial interest and rights of unit holders

The beneficial interest and rights of the Class B unit holder are specified in the Contribution Agreement entered into with Class B unit holder. The entire unit capital comprising Class B units are held by Tata Capital Limited, the Investment Manager.

Distributions by the Fund will be in the order of priority as defined in the Contribution Agreement/Private Placement Memorandum of the Fund. Holders of Class A units are entitled to return of paid up capital prior to return of paid up capital to the Holders of Class B units. Preferred Return needs to be paid to Class A holders prior to paying any Distributable Proceeds in excess of paid up capital of Class A and Class B unit holders, to Class B unit holders.

4. Reserves and surplus

Particulars	As at 31 March 2026 ₹	As at 31 March 2025 ₹
Opening (loss) in statement of profit and loss	(774,227,098)	(803,297,379)
Add: profit/(loss) for the year	(2,243,422)	205,977,262
Less: payout of Income/ gain to Contributors	(21,845,689)	(176,906,981)
Closing (loss) in Statement of Profit and Loss	(798,316,209)	(774,227,098)



[Handwritten signature]

Tata Capital Healthcare Fund I

Notes to the financial statements (continued)

for the year ended on 31 March 2026

Currency: In Indian Rupees

5. Trade payables

Particulars	As at 31 March 2026 ₹	As at 31 March 2025 ₹
Reimbursement of expenses (refer note 16)	857,093	112,469
Tax consultant fees	27,540	-
Fund administrative fees	103,391	102,938
Total	988,024	215,407

The information required to be disclosed under the Micro, Small and Medium Enterprises Development Act, 2006 has been determined to the extent such parties have been identified on the basis of information available with the Trust. The amount of principal and interest outstanding during the year is given below:

Particulars	As at 31 March 2026 ₹	As at 31 March 2025 ₹
Total outstanding dues of micro, small and medium enterprises	-	-
Total outstanding dues of creditors other than micro, small and medium enterprises	988,024	215,407
Total	988,024	215,407

6. Other current liabilities

Particulars	As at 31 March 2026 ₹	As at 31 March 2025 ₹
Statutory dues payable	80,486	53,966
Audit fee payable	378,000	378,000
Trusteeship payable	-	-
Retentions*	2,466,018	3,468,584
Total	2,924,504	3,900,550

* Retentions represent distributable proceeds withheld and intended to be used to meet possible future expenses. Any retention identified as in excess of requirement, will be distributed to Contributors. Refer note 13 for utilization during the year.

7. Long - term loan and advances

Particulars	As at 31 March 2026 ₹	As at 31 March 2025 ₹
Advance taxes (net of provision for taxation ₹8,021,111 Previous year ₹8,282,149)	-	632,565
Total	-	632,565



Tata Capital Healthcare Fund I

Notes to the financial statements (continued)

for the year ended on 31 March 2026

Currency: In Indian Rupees

8. Current portion of long term investments

i) Classification

Particulars	As at 31 March 2026 ₹	As at 31 March 2025 ₹
Investments (valued at cost unless stated otherwise)		
Investment in equity shares	233,501,765	233,501,765
Total	233,501,765	233,501,765
Less: Provision for diminution in the value of investment:		
Equity shares held in Novalead Pharma Private Limited	233,501,765	233,501,765
	233,501,765	233,501,765
Total	-	-

ii) Details of investments

Name of portfolio company	Instrument	No. of units of instrument	Extent of Holding (%)	Acquisition cost ₹
Novalead Pharma Private Limited	Equity shares	11,477 <i>11,477</i>	18.99% <i>19.75%</i>	233,501,765 <i>233,501,765</i>
Total				233,501,765 <i>233,501,765</i>

Figures in italics are for previous year.

iii) Other matters

Book value of unquoted Investment As at 31 March 2026: ₹ NIL (31 March, 2025: ₹NIL)

iv) Fair value disclosure

a) The fair value of the following portfolio investments have been determined by an independent value on the following basis:

- For instruments traded on active markets, the fair value is determined with reference to quoted market prices on National Stock Exchange of India Limited (and if not quoted in National Stock Exchange of India Limited then BSE Limited); and
- For other instruments, using generally accepted valuation approaches and valuation methods viz. income approach, cost approach and market approach – considered and applied in each case to the extent relevant and applicable.



[Handwritten signature]

Tata Capital Healthcare Fund I

Notes to the financial statements (continued)

for the year ended on 31 March 2026

Currency: In Indian Rupees

9. Cash and bank balances

Particulars	As at 31 March 2026 ₹	As at 31 March 2025 ₹
Cash and bank balances as per Accounting Standard (AS) 3 on Cash Flow Statements		
Current accounts	1,489,308	1,335,612
Short term fixed deposit accounts with schedule bank (with original maturity of less than 3 months)	1,435,581	25,768,879
Total	2,924,889	27,104,491

10. Short- term loans and advances

Particulars	As at 31 March 2026 ₹	As at 31 March 2025 ₹
Advance taxes (net of provision for taxation ₹8,021,111 Previous year ₹8,282,149)	124,954	-
Others	-	1,300
Total	124,954	1,300

11. Revenue from operations

Particulars	For the year ended March 31, 2026 ₹	For the year ended March 31, 2025 ₹
Interest income on fixed deposit	1,025,380	1,482,836
Dividend from portfolio company	-	9,614,854
Total	1,025,380	11,097,690

12. Gain on sale of investment

Particulars	For the year ended March 31, 2026 ₹	For the year ended March 31, 2025 ₹
Net gain on sale of long-term investment	-	198,230,312
Total	-	198,230,312

13. Other income

Particulars	For the year ended March 31, 2026 ₹	For the year ended March 31, 2025 ₹
Interest on income tax refund	30,821	-
Total	30,821	-



Tata Capital Healthcare Fund I

Notes to the financial statements (continued)

for the year ended on 31 March 2026

Currency: In Indian Rupees

14. Expenses

i) Operating expenses (includes Goods & Services Tax)

Particulars	For the year ended March 31, 2026 ₹	For the year ended March 31, 2025 ₹
Investment management fees (refer note no. 17 and 14 (ii))	-	-
Professional fees	2,923,211	2,678,897
Trusteeship fees (refer note no. 17 and 14 (iii))	590,000	590,000
Audit fees (refer note no. 14 (iv))	413,000	413,000
Other expenses	3,624	4,587
Utilisation of distributable proceeds retained (refer note no. 6)*	(1,003,000)	(1,003,000)
Total	2,926,835	2,683,484

*Investment management fees, audit fee and trusteeship fees expense are adjusted again distributable proceeds retained.

ii) Management fees

Management Fee is charged up to 12 July 2020. In accordance with the conditions of extension of term of the Fund, no management fee is chargeable for the period 13 July 2020 to 31 March 2026.

iii) Trusteeship fees

In accordance with the Indenture of Trust dated 3 June 2009, as amended on 17 February 2010 between the Settlor and the Trustees an annual recurring fee of ₹500,000/- (plus applicable taxes) ((PY ₹500,000/- (plus applicable taxes)) is payable to the Trustee. The Trusteeship fee may be varied by mutual agreement between the Investment Manager and the Trustee.


iv) Audit fees (including taxes)

Particular	For the year ended March 31, 2026 ₹	For the year ended March 31, 2025 ₹
As Auditor		
Audit fees	413,000	413,000
Total	413,000	413,000

v) Income tax

As per the provisions of section 10(23FB) of the Income-tax Act, 1961 (the "Act"), income earned by a SEBI registered venture capital fund ("VCF") from investments in venture capital undertaking ("VCU") ("qualifying income") is exempt from tax in the hands of the VCF and the beneficiaries of the Fund would be taxable as per section 115U of the Act in the same manner as if it were the income accruing / arising / received by the beneficiaries had the beneficiary made investment directly in the VCU.

In view of the above, the qualifying income earned by the Fund is exempt from tax in the hands of the Fund. The non – qualifying income i.e. income of the VCF other than from investment in VCUs would not be eligible for exemption under Section 10(23FB) of the Act and shall be taxed in the hands of the VCF in accordance with the provisions of the Act governing taxation of trusts.



Tata Capital Healthcare Fund I

Notes to the financial statements *(continued)*

for the year ended on 31 March 2026

Currency: In Indian Rupees

14. Expenses *(continued)*

The Fund is a determinate trust and therefore the non-qualifying income would be taxed in the hands of the Trustees of the Fund in representative capacity in like manner and to the same extent as that of the beneficiaries as if the beneficiaries have directly earned such income.

15. Segment reporting

The Fund is engaged in a single business segment viz. investing in companies having high growth potential and in the expansion/development phase. Also it operates within India which is a single geographic segment. In absence of separate reportable segment, the disclosure required under Accounting Standard (AS) 17 on "Segment Reporting" have not been made.



Tata Capital Healthcare Fund I

Notes to the financial statements (*continued*)

for the year ended on 31 March 2026

Currency: In Indian Rupees

16. Related party disclosures

Disclosure as required by Accounting Standard (AS) – 18 on “Related Party Disclosures” detailed below:

Names of the related parties and description of relationship:

<u>Related Party</u>	<u>Relationship</u>
Entities having substantial control	
Tata Sons Private Limited (formerly Tata Sons Limited)	Ultimate Holding Company of Tata Capital Limited
Tata Capital Limited	Investment Manager and Contributor
Entities having significant influence	
Tata Trustee Company Private Limited (formerly Tata Trustee Company Limited)	Enterprise having significant influence
Entities on which the Fund has significant influence	
Novalead Pharma Private Limited	Associate
Entities in the same group	
Tata Securities Limited	Depository

The Fund's related party balances and transactions are summarized as follows:

Sr. no	Party name	Nature of transaction	Amount (₹)
1	Tata Capital Limited	Payout of income/gain towards Class A units held	- 35,672,291
		Capital outstanding - Class A units	255,725,021 255,725,021
		Distribution paid towards Class B units held	21,669,093 67,388,760
		Capital outstanding - Class B units	- -
		Reimbursement of expenses	- 641,018
		Balance payable/(receivable)	857,093 112,469
2	Tata Trustee Company Private Limited	Trusteeship fees (excluding taxes)	500,000 500,000
3	Tata Securities Limited	Depository fees (excluding taxes)	200 -

Previous year's figures are in italics

Please refer note 8 (ii) for investments made by the Fund in portfolio companies as at reporting date.



[Handwritten signature]

Tata Capital Healthcare Fund I

Notes to the financial statements (*continued*)

for the year ended on 31 March 2026

Currency: In Indian Rupees

17. Contingent liabilities and capital commitment

Income tax demands not acknowledged by the Fund relating to cases contested by the Fund and which are not likely to devolve on the Fund amounted to ₹ NIL (including surcharge, cess and interest) (As at 31 March 2025 ₹191,966,862 ((including surcharge, cess and interest))).

The Fund has no contracts remaining to be executed on capital account which are not provided for As at 31 March 2026 (As at 31 March 2025 - Nil).

18. The Fund is set up as a Trust and is not required to comply with the requirement of Schedule III of the Companies Act, 2013 in preparing and presenting its financial statements.

For **KKC & Associates LLP**

(formerly Khimji Kunverji & Co LLP)

Chartered Accountants

Firm Registration No: 105146W/W100621

Soorej Kombaht

Partner

Membership No: 164366

Mumbai

20 April 2026



For and on behalf of the Fund

Tata Capital Healthcare Fund I

Rajiv Sabharwal

Managing Director & CEO

Tata Capital Limited-

Investment Manager

Visalakshi Chandramouli

Managing Partner

Tata Capital Limited-

Investment Manager

Director

Tata Trustee Company

Private Limited

Mumbai

Director

Tata Trustee Company

Private Limited

Mumbai

